SCHEMBL1592785

SCHEMBL1592785

CN1CCCN(Cc2nc3cc(N)ccc3c(=O)n2-c2ccc(F)cc2Cl)CC1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 7/20 0.48
IDO1 P14902 1/20 0.44
TDO2 P48775 1/20 0.44
IDO2 Q6ZQW0 1/20 0.44
ALDH1A1 P00352 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HSD17B10 Q99714 1/20 0.43
HTR7 P34969 1/20 0.39
GRM2 Q14416 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TRPV4 Q9HBA0 2/20 0.39
KCNH2 Q12809 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
TNKS O95271 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1592775 0.86 HIF1A (0.60) HIF1AIDO1TDO2IDO2ALDH1A1
SCHEMBL1593420 0.85 HIF1A (0.50) HIF1AIDO1TDO2IDO2ALDH1A1
SCHEMBL1592811 0.84 HIF1A (0.44) HIF1AIDO1TDO2IDO2ALDH1A1
SCHEMBL1593540 0.82 HIF1A (0.74) HIF1AALDH1A1HTR7SMN1; SMN2
SCHEMBL1593340 0.79 HIF1A (0.75) HIF1AALDH1A1MEN1KMT2AHSD17B10
SCHEMBL15368090 0.79 HIF1A (0.59) HIF1AALDH1A1KMT2AHTR7SMN1; SMN2
SCHEMBL15368091 0.76 HIF1A (0.60) HIF1AALDH1A1MEN1KMT2AHSD17B10
SCHEMBL1592822 0.75 HIF1A (0.56) HIF1AALDH1A1MEN1KMT2AHSD17B10
SCHEMBL1593317 0.75 ALDH1A1 (0.54) HIF1AALDH1A1MEN1KMT2AHSD17B10
SCHEMBL14464268 0.72 HIF1A (0.47) HIF1AALDH1A1MEN1KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575143-B2 3-aryl-substituted quinazolones, and uses thereof PROLEXYS PHARMACEUTICALS, INC. (US) 2013-11-05 US disclosed
US-8575143-B2 3-aryl-substituted quinazolones, and uses thereof PROLEXYS PHARMACEUTICALS, INC. (US) 2013-11-05 US disclosed
US-8575143-B2 3-aryl-substituted quinazolones, and uses thereof PROLEXYS PHARMACEUTICALS, INC. (US) 2013-11-05 US disclosed
US-20110092489-A1 3-Aryl-Substituted Quinazolones, and Uses Thereof Prolexys Pharmaceuticals ,Inc. (US) 2011-04-21 US disclosed
US-20110092489-A1 3-Aryl-Substituted Quinazolones, and Uses Thereof Prolexys Pharmaceuticals ,Inc. (US) 2011-04-21 US disclosed
US-20110092489-A1 3-Aryl-Substituted Quinazolones, and Uses Thereof Prolexys Pharmaceuticals ,Inc. (US) 2011-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092489-A1 3-Aryl-Substituted Quinazolones, and Uses Thereof MKI67, MCL1, HCCS HIF1A 1381/4885IDO1 854/4885TDO2 971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.